第二型糖尿病病人使用Exenatide之療效與安全性評估

Efficacy and Safety of Exenatide Therapy in Patients with Type 2 Diabetes

10.6168/FJCP.2013.2104.04

林麗梅(Li-Mei Lin)；陳立偉(Li-Wei Chen)；羅嘉盈(Chia-Ying Lo)；陳玉瑩(Yuk-Ying Chan)

第二型糖尿病 ； 空腹血糖值 ； 糖化血色素 ； 身體質量指數 ； Type 2 Diabetes ； Exenatide ； Fasting Plasma Glucose ； Glycated Hemoglobin A1c ； Body Mass Index (BMI)

臺灣臨床藥學雜誌

21卷4期（2013 / 12 / 31）

313 - 320

繁體中文

Objects: Exenatide is an incretin mimetic and GLP-1 analogue, it appears to improve fasting and postprandial glycemic control. It also can lead to weight loss by slowing gastric emptying and suppressing appetite. This study aimed to evaluate the efficacy and safety of exenatide therapy in patients with type 2 diabetes.Methods: In this retrospective cohort study, patients were included as those visited Keelung Chang Gung Memorial Hospital, during the period of January 1, 2011 to July 31, 2012. Subjects with type 2 diabetes were enrolled if they were treated combined use of oral hypoglycemic drugs or insulin and exenatide. Exclusion criteria were those who (1) were less than 18 years old; (2) changed more than 2 kinds of hypoglycemic agents with exenatide treatment; (3) or used exenatide less than 6 months.Results: A total of 25 patients were included in the study. The mean baseline values ( ± SE) for weight, BMI and HbA1c were 86.2 (14.0) kg, 33.2 (4.5) kg/m^2, and 10.8% (1.4%), respectively. Significant decreases in body weight and BMI of 4.72 kg and 1.81 kg/m^2 were observed at 6 months, respectively (p ＜ 0.0001). Similar, the mean glycated hemoglobin (HbA1c) level decreased 1.10% ± 4.78 (p = 0.0049). The most frequent adverse events were gastrointestinal in nature, such as nausea and vomiting. Incidence of hypoglycemia was low.Conclusions: The results suggest that a 6-month exenatide therapy combined use of oral hypoglycemic drugs or insulin significantly improved patients' body weights and HbA1c levels.

Objects: Exenatide is an incretin mimetic and GLP-1 analogue, it appears to improve fasting and postprandial glycemic control. It also can lead to weight loss by slowing gastric emptying and suppressing appetite. This study aimed to evaluate the efficacy and safety of exenatide therapy in patients with type 2 diabetes.Methods: In this retrospective cohort study, patients were included as those visited Keelung Chang Gung Memorial Hospital, during the period of January 1, 2011 to July 31, 2012. Subjects with type 2 diabetes were enrolled if they were treated combined use of oral hypoglycemic drugs or insulin and exenatide. Exclusion criteria were those who (1) were less than 18 years old; (2) changed more than 2 kinds of hypoglycemic agents with exenatide treatment; (3) or used exenatide less than 6 months.Results: A total of 25 patients were included in the study. The mean baseline values ( ± SE) for weight, BMI and HbA1c were 86.2 (14.0) kg, 33.2 (4.5) kg/m^2, and 10.8% (1.4%), respectively. Significant decreases in body weight and BMI of 4.72 kg and 1.81 kg/m^2 were observed at 6 months, respectively (p ＜ 0.0001). Similar, the mean glycated hemoglobin (HbA1c) level decreased 1.10% ± 4.78 (p = 0.0049). The most frequent adverse events were gastrointestinal in nature, such as nausea and vomiting. Incidence of hypoglycemia was low.Conclusions: The results suggest that a 6-month exenatide therapy combined use of oral hypoglycemic drugs or insulin significantly improved patients' body weights and HbA1c levels.